What are the appropriate medications for managing lumbar strain and sprain?

Medications for Lumbar Strain and Sprain

For acute lumbar strain and sprain, NSAIDs are the first-line medication, with skeletal muscle relaxants as an effective add-on for short-term pain relief when NSAIDs alone are insufficient. 1

First-Line Treatment: NSAIDs

NSAIDs should be your primary pharmacologic choice for both acute and chronic lumbar strain/sprain. The evidence is robust:

• Acute LBP: NSAIDs provide small but statistically significant pain reduction (7.3 points on 0-100 scale) and disability improvement (2 points on 0-24 RMDQ scale) compared to placebo 12
• Chronic LBP: Similar modest benefits persist at intermediate-term follow-up (>3 months), with pain reduction of approximately 7 points and disability improvement of 0.85 points 13

Key point: While the effect size is small and may not reach clinical significance thresholds, NSAIDs consistently outperform other options with an acceptable safety profile for short-term use 2

There is no meaningful difference between selective COX-2 inhibitors and non-selective NSAIDs for efficacy or adverse events, so choose based on individual cardiovascular and gastrointestinal risk factors 2

Second-Line: Skeletal Muscle Relaxants

Add skeletal muscle relaxants when NSAIDs alone provide inadequate relief for acute lumbar strain:

• Effectiveness: Muscle relaxants are effective for short-term pain relief in acute LBP, with patients 40% more likely to achieve pain relief compared to placebo 14
• Combination therapy: Adding a muscle relaxant (particularly tizanidine) to NSAIDs or acetaminophen provides consistently greater pain relief than analgesics alone 4
• Trade-off: Sedation is the primary adverse effect, occurring 2.4 times more frequently than with analgesics alone 4

Cyclobenzaprine has the most robust clinical trial evidence among muscle relaxants, though carisoprodol and metaxalone also appear effective 5. Avoid carisoprodol due to abuse potential 5

What NOT to Use

Acetaminophen: High-certainty evidence shows acetaminophen is completely ineffective for acute LBP—no difference from placebo for pain, disability, or global improvement 13. This represents a major shift from older guidelines that recommended it as first-line.

Systemic corticosteroids: Do not use—they are ineffective for low back pain with or without radiculopathy 14

Benzodiazepines: Ineffective for radiculopathy and only fair evidence for general LBP 1. The sedation risk outweighs minimal benefits.

Limited Role Medications

Opioids: Reserve only for severe, refractory cases after discussion of risks:

• Evidence limited to short-term trials showing modest effects for chronic LBP 1
• Small to moderate pain reduction (SMD -0.41 to -0.55) but established harm profile including 10% risk of nausea, 7% constipation, 8% dizziness 3
• Trials were not designed to assess serious harms like addiction 1

Antidepressants: Low-certainty evidence shows no benefit for chronic LBP overall (SMD -0.04 for pain), though duloxetine specifically showed modest effects in newer evidence 13

Clinical Algorithm

1. Start with NSAIDs (ibuprofen 400-600mg TID or naproxen 500mg BID) for all patients without contraindications
2. Add muscle relaxant (cyclobenzaprine 5-10mg TID) if inadequate response after 2-3 days in acute phase
3. Reassess at 1-2 weeks: If no improvement, reconsider diagnosis rather than escalating medications
4. Avoid acetaminophen entirely—it adds no benefit
5. Reserve opioids only for severe cases unresponsive to above, with explicit discussion of risks and time-limited trial

Important Caveats

• All medication effects are small to moderate and primarily short-term 1
• Functional improvements are generally smaller than pain improvements 4
• The evidence base focuses on short-term use; longer-term safety data for NSAIDs in this population is limited 2
• Screen for NSAID contraindications: cardiovascular disease, renal impairment, peptic ulcer disease, anticoagulation
• Muscle relaxant sedation can impair driving and work performance—warn patients explicitly 4

The 2017 ACP guideline 1 represents the highest quality, most recent systematic evidence and should guide your prescribing, superseding older recommendations that included acetaminophen as first-line therapy.